IRIS
COSTANTINI, Andrea
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.261
EU - Europa 2.525
AS - Asia 2.519
SA - Sud America 597
AF - Africa 113
OC - Oceania 29
Continente sconosciuto - Info sul continente non disponibili 1
Totale 11.045
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.172
SG - Singapore 818
IT - Italia 561
VN - Vietnam 518
CN - Cina 516
BR - Brasile 459
RU - Federazione Russa 407
UA - Ucraina 312
SE - Svezia 251
HK - Hong Kong 224
DE - Germania 205
IE - Irlanda 184
FR - Francia 169
GB - Regno Unito 103
DK - Danimarca 96
BD - Bangladesh 91
FI - Finlandia 90
TR - Turchia 77
IN - India 61
KR - Corea 55
AR - Argentina 52
NL - Olanda 52
CI - Costa d'Avorio 39
CA - Canada 37
MX - Messico 31
AU - Australia 27
CO - Colombia 25
EC - Ecuador 24
AT - Austria 21
IQ - Iraq 21
JP - Giappone 20
ID - Indonesia 17
ZA - Sudafrica 17
PL - Polonia 15
MA - Marocco 14
VE - Venezuela 13
EG - Egitto 12
BE - Belgio 11
PY - Paraguay 11
AE - Emirati Arabi Uniti 10
ES - Italia 10
PK - Pakistan 10
UZ - Uzbekistan 10
KE - Kenya 9
TN - Tunisia 8
CL - Cile 7
MY - Malesia 7
PH - Filippine 7
CH - Svizzera 6
JO - Giordania 6
KZ - Kazakistan 6
NP - Nepal 6
RO - Romania 6
SA - Arabia Saudita 6
TH - Thailandia 6
AL - Albania 5
AZ - Azerbaigian 5
DZ - Algeria 5
IL - Israele 5
LT - Lituania 5
DO - Repubblica Dominicana 4
BG - Bulgaria 3
GT - Guatemala 3
JM - Giamaica 3
SV - El Salvador 3
UY - Uruguay 3
AM - Armenia 2
GA - Gabon 2
HR - Croazia 2
KW - Kuwait 2
LB - Libano 2
NG - Nigeria 2
NO - Norvegia 2
OM - Oman 2
PA - Panama 2
PS - Palestinian Territory 2
TW - Taiwan 2
BB - Barbados 1
BF - Burkina Faso 1
BJ - Benin 1
BO - Bolivia 1
BS - Bahamas 1
CD - Congo 1
CG - Congo 1
CR - Costa Rica 1
CZ - Repubblica Ceca 1
EE - Estonia 1
EU - Europa 1
FJ - Figi 1
GY - Guiana 1
HN - Honduras 1
HU - Ungheria 1
IR - Iran 1
IS - Islanda 1
KG - Kirghizistan 1
KH - Cambogia 1
LV - Lettonia 1
MM - Myanmar 1
MN - Mongolia 1
NI - Nicaragua 1
Totale 11.037
Salva come PNG Salva come JPEG
Città #
Ashburn 913
Singapore 464
Dallas 454
Chandler 376
Jacksonville 317
Fairfield 247
San Jose 241
Hong Kong 218
Boardman 187
Dublin 181
Ho Chi Minh City 170
New York 146
Wilmington 144
Des Moines 128
Beijing 123
Woodbridge 112
Hanoi 107
Seattle 102
Los Angeles 100
Ann Arbor 85
Houston 83
Lauterbourg 82
The Dalles 74
San Mateo 73
Lawrence 71
Princeton 71
Rome 68
Redmond 58
Moscow 55
Hefei 53
Milan 50
Cambridge 49
Centro 40
San Diego 40
Abidjan 39
Chicago 39
Council Bluffs 39
Orem 38
São Paulo 37
Da Nang 36
Ancona 33
Munich 32
Buffalo 30
Helsinki 29
London 24
Haiphong 23
Denver 22
Santa Clara 22
Guangzhou 21
Marche 21
Phoenix 20
Chennai 17
Rio de Janeiro 17
Turin 17
Turku 16
Atlanta 15
Florence 15
Melbourne 15
Biên Hòa 13
San Francisco 13
Shanghai 13
Amsterdam 12
Guayaquil 12
Istia D'ombrone 12
Johannesburg 12
Norwalk 12
Tokyo 12
Warsaw 12
Washington 12
Wuhan 12
Bogotá 11
Brooklyn 11
Brussels 11
Charlotte 11
Columbus 11
Frankfurt am Main 11
Paris 10
Tashkent 10
Boston 9
Civitanova Marche 9
Dhaka 9
Hải Dương 9
Istanbul 9
Montreal 9
Nuremberg 9
Porto 9
Quanzhou 9
Toronto 9
Belo Horizonte 8
Brookline 8
Buenos Aires 8
Chiaravalle 8
Elk Grove Village 8
Kingscliff 8
Miami 8
Miano 8
Salt Lake City 8
Bologna 7
Bến Tre 7
Genoa 7
Totale 6.715
Salva come PNG Salva come JPEG
Nome #
Specific Anti-Nuclear Antibodies, Clinical Features and Outcome Following Treatment with Nilotinib In Patients with Chronic Graft-Versus-Host Disease. The 44th Annual Meeting of the European Society for Blood and Marrow Transplantation: Physicians Poster Sessions 309
A novel method to evaluate prethawing viability of cryopreserved CD34+ hematopoietic stem cells for autologous transplantation. 221
Immunomodulatory Effects of Tyrosine Kinase Inhibitor In Vitro and In Vivo Study 192
Cost of HAART in Italy: multicentric evaluation and determinants from a large HIV outpatient cohort. 186
Gut epithelial impairment, microbial translocation and immune system activation in inflammatory bowel disease–associated spondyloarthritis 186
Age-related M1/M2 phenotype changes in circulating monocytes from healthy/unhealthy individuals 178
A new method to assess the viability of collected CD34+ cells before reinfusion: a prospective study in 50 autotransplanted patients. 176
Tollerabilità metabolica e durevolezza degli schemi antiretrovirali comprendenti nevirapina (Durability and tolerability of long-term nevirapine-based HAART). 175
Abnormalities of erythropoiesis during HIV-1 disease: a longitudinal analysis. 174
Evaluation of HIV Transmission Clusters among Natives and Foreigners Living in Italy 171
Late or missed HIV diagnosis during pregnancy is still occurring in a high-income country and represents a high risk of MTCT 168
Durability of lopinavir/ritonavir monotherapy in individuals with viral load ≤50 copies/ml in an observational setting 168
Nilotinib Treatment of Patients Affected by Chronic Graft-versus-Host Disease Reduces Collagen Production and Skin Fibrosis by Downmodulating the TGF-β and p-SMAD Pathway 167
Quantification of the HIV-1 total reservoir in the peripheral blood of naïve and treated patients by a standardised method derived from a commercial HIV-1 RNA quantification assay. 166
In vitro comparison of different TKI activity in T-Cell populations: selective sparing of Treg by Nilotinib. 165
CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: An observational cohort study 164
Higly active antiretroviral therapy induces specific changes in effector and central memory T cell sub-populations 150
Active HCV Replication but Not HCV or CMV Seropositive Status Is Associated with Incident and Prevalent Type 2 Diabetes in Persons Living with HIV. 147
Discontinuation of Initial Antiretroviral Therapy in Clinical Practice: Moving Toward Individualized Therapy. 143
Direct acting antivirals (DAAs) for the treatment of HCV infection in HIV/HCV coinfected patients: a clinical experience. 142
Response to: Letter to the Editor on “Bonafè M, Prattichizzo F, Giuliani A, Storci G, Sabbatinelli J, Olivieri F. Inflamm-aging: Why older men are the most susceptible to SARS-CoV-2 complicated outcomes. Cytokine Growth Factor Rev” by Eugenia Quiros-Roldan, Giorgio Biasiotto and Isabella Zanella 141
Diagnosi sierologica nelle malattie autoimmuni non organo-specifiche. 138
Activated switched memory B cell clusters in chronic spontaneous urticaria are increased in subjects with long disease duration and relapse upon omalizumab discontinuation: Results of the IL-10-OMZ study 136
OC-34 Clinical outcome of switching to a dual drug regimen (2DR) vs. switching or remaining on a triple (3DR) regimen in the setting of a viral load ≤50 copies/mL 136
Long-term CD4+ T-cell count evolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease inhibitors to regimens containing NRTI plus non-NRTI or only NRTI. 135
Durability of first-line regimens including integrase strand transfer inhibitors (INSTIs): data from a real-life setting. 135
POOR RESPONSE TO FIRST BNT162B2 SARS-COV-2 VACCINE DOSE IN RECIPIENTS OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT 134
Comparsa di polmonite in soggetto con storia recente di inappetenza, disfagia, calo ponderale, ed eritema diffuso. 133
Effects of cryopreservation on lymphocyte immunophenotype and function 131
OC-43 ‘U=U impossibile sbagliare’ awareness campaign: impact assessment among PLWH 129
CROI 2013: le ricadute per la pratica clinica. 128
First-line antiretroviral therapy with efavirenz plus tenofovir disiproxil fumarate/emtricitabine or rilpivirine plus tenofovir disiproxil fumarate/emtricitabine: a durability comparison 127
Characterisation and outcomes of difficult-to-treat patients in an Italian cohort of PLWHIV starting modern ART regimens. 125
SARS-CoV-2 mRNA Vaccine Response in People Living with HIV According to CD4 Count and CD4/CD8 Ratio 123
Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50cp/mL. 122
Incidence and progression to cirrhosis of new hepatitis C virus infections in persons living with human immunodeficiency virus. 121
Day-On, Day-Off emtricitabine, tenofovir disoproxil fumarate and efavirenz single tablet regimen (DODO) as maintenance therapy in HIV-infected patients 118
Il ruolo del Medico di Medicina Generale nella diagnosi precoce della malattia da HIV. 117
PROGETTO E-PROs: COSTRUZIONE DI UNA PIATTAFORMA DIGITALE PER LA GESTIONE DI STRUMENTI CENTRATI SUL PAZIENTE NELLA PRATICA CLINICA (The E-PROs Project: creation of a digital platform to manage patient-oriented tools in clinical practice). 117
Is physician assessment of alcohol consumption useful in predicting risk of severe liver disease among people with HIV and HIV/HCV co-infection? 116
The effect of dupilumab in an HBV-HIV coinfected atopic patient: a case report 115
Efficacy and costs of Direct Acting Antivirals (DAAS) for the treatment of HCV Iinfection amnog HCV-monoinfected and HIV/HCV co-infected patients in real-life setting 114
Hepatitis C virus core antigen: analytical performances, correlation with viremia and potential applications of a quantitative, automated immunoassay. 113
Humoral and cellular immunity after mRNA COVID-19 vaccine in psoriatic patients on biological or immunosuppressive therapy: a real-life experience 111
Microbial translocation predicts disease progression of HIV-infected antiretroviral-naive patients with high CD4+ cell count. 111
P131 Anlaids community-based HIV screening as a tool to improve HIV diagnosis among asymptomatic individuals 110
Impact of NRTI resistance mutations on virological effectiveness of antiretroviral regimens containing elvitegravir: a multi-cohort study. 110
OC52 Long-term effectiveness of bictegravir-emtricitabine-tenofovir alafenamide (B/F/TAF) as first-line therapy and as switch strategy in virologically suppressed persons with HIV up to 192-weeks: data from the ICONA-BIC Study 109
Molecular analysis of hepatitis B virus (HBV) in an HIV co-infected patient with reactivation of occult HBV infection following discontinuation of lamivudine-including antiretroviral therapy. 109
Longitudinal analysis of HIV-1 coreceptor tropism by single and triplicate HIV-1 RNA and DNA sequencing in patients undergoing successful first-line antiretroviral therapy 107
Do we still need CD4 T cell count? 106
Evolution of major non-HIV-related comorbidities in HIV-infected patients in the Italian Cohort of Individuals, Naïve for Antiretrovirals (ICONA) Foundation Study cohort in the period 2004–2014. 106
SC6 Promoting hepatitis and HIV screening in high prevalence populations: the ‘test in the city’ project 105
Specific changes in the post-translational regulation of nucleolin in lymphocytes from patients infected with human immunodeficiency virus 105
Genotypic testing on HIV-1 DNA as a tool to assess HIV-1 co-receptor usage in clinical practice: results from the DIVA study group 105
Pregnancy outcomes among ART-naive and ART-experienced HIV-positive women: data from the ICONA foundation study group, years 1997-2013 103
ORCHESTRA Delphi consensus: clinical management of SARS-CoV-2 infection in people with HIV 102
Polyclonal serum-free light chains elevation in HIV-infected patients. 101
Treatment discontinuation in HIV-1-infected individuals starting their first-line HAART after 2008: data from the ICONA Foundation Study Cohort 101
Validation of a self-reported HIV symptoms list: the ISS-HIV symptoms scale. 101
Genotypic Resistance Tests for the Management of Structured Therapeutic Interruptions after Multiple Drug Failure: Prosecution 100
Increased risk of virologic failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: Data from the ICONA cohort 100
The impact of DAA-mediated HCV eradication on CD4+ and CD8+ T lymphocyte trajectories in HIV/HCV coinfected patients: Data from the ICONA Foundation Cohort 100
Diagnostica immunologica. 99
P128 The role of ancona checkpoint in counseling and facilitating PrEP access through tele-visits 98
HIV-induced abnormalities in myelopoiesis and their recovery following antiretroviral therapy 98
Characterization and outcomes of difficult-to-treat patients starting modern first-line ART regimens: Data from the ICONA cohort 96
Incidence and predictors of single drug discontinuation according to the presence of HCV coinfection in HIV patients from the ICONA Foundation Cohort Study. 96
Inflammation and microbial translocation measured prior to combination antiretroviral therapy (cART) and long-term probability of clinical progression in people living with HIV. 96
Lo studio fenotipico di linfociti e altre cellule mononucleate. 93
Evaluation of the prognostic value of impaired renal function on clinical progression in a large cohort of HIV-infected people seen for care in Italy 92
Non-AIDS defining cancers in the D:A:D Study - time trends and predictors of survival: A cohort study 91
Impaired in-vitro growth of megakaryocytic colonies derived from CD34 cells of HIV-1-infected patients with active viral replicatio 90
Incidence of malignancies in HIV-infected patients and prognostic role of current CD4 cell count: evidence from a large Italian cohort study. 87
LA SIEROLOGIA TIPO-SPECIFICA PER HERPES SYMPLEX TIPO 2 NELLA GESTIONE DEI PAZIENTI HIV POSITIVI 86
HIV among adolescents and young adults in Italy: focus on epidemiological, viro-immunological and treatment characteristics of 689 18-24 year old subjects enrolled in the ICONA Cohort. 85
Soluble CD163 in CMV Infected and Uninfected subjects on Virologically-Suppressive Antiretroviral therapy in the ICONA cohort 84
Effectiveness and predictors of treatment discontinuation of long-acting cabotegravir/rilpivirine in virologically suppressed people with HIV: real-life data from the Icona Cohort 83
PRIMARY BILIARY CHOLANGITIS CASE- FINDING: AN ITALIAN MULTICENTER OBSERVATIONAL STUDY ON PATIENTS WITH INCIDENTAL FINDING OF ANTI- MITOCHONDRIAL ANTIBODIES. 82
La ricerca degli anticorpi anti-nucleo non è sempre di facile interpretazione 82
Tollerabilità metabolica e durevolezza degli schemi antiretrovirali comprendenti nevirapina. 81
Switch a raltegravir in un paziente con carcinoma a cellule di Merkel e sarcoma di Kaposi. 80
Il paziente adulto con immunodeficienza. 78
Long-term outcomes of bictegravir/emtricitabine/tenofovir alafenamide as first-line therapy and as switch strategy in virologically suppressed persons with HIV: data from the ICONA cohort 76
La tollerabilità della terapia antiretrovirale come mezzo per la gestione a lungo termine di pazienti complessi: un caso clinico. 74
Risk of clinical events in virologically suppressed people with HIV switching to a two-drug regimen vs. remaining on a three-drug regimen: a target trial emulation 74
Trends in Mortality in People With HIV From 1999 through 2020: A Multicohort Collaboration 73
Long-acting injectable antiretrovirals for HIV treatment in the ICONA cohort: physicians’ and nurses’ points of view 72
Il ruolo del Mmg nella diagnosi precoce della malattia da HIV. 68
ORCHESTRA Delphi consensus: diagnostic and therapeutic management of post-COVID-19 condition in vulnerable populations 67
Infezione da HIV-1. 67
L’immunoricostituzione, un paesaggio dai mutevoli confini 64
Management of vaccinations in patients with non‐Hodgkin lymphoma 56
Selected comorbidities and the probability of ART switch in PWH with undetectable HIV-RNA: a retrospective analysis in Italy 52
La riduzione delle interazioni farmacologiche come mezzo per aumentare l’aderenza alla terapia antiretrovirale e garantirne la durability. 51
HIV infection among adolescents and young adults in Italy: Epidemiology, viro-immunological and treatment outcomes 27
Effectiveness of first-line lamivudine/dolutegravir antiretroviral therapy in persons with HIV: real-life data from the ICONA Foundation cohort 27
Self-reported wellbeing and integration levels of migrants with HIV in Italy: a cross-sectional analysis fromthe ICONA cohort 24
Long-term effectiveness of bictegravir-emtricitabine-tenofovir alafenamide (BIC/FTC/TAF) as switch strategy in virologically suppressed people with HIV across age strata: observational data from the ICONA-BIC study 20
Proportion of newly diagnosed persons with HIV with HIV-RNA greater than/equal to 500 000 copies/mL in 2018–2023 in Italy: data from the ICONA Foundation Cohort Study 11
Totale 11.234
Salva come PNG Salva come JPEG
Categoria #
all - tutte 45.645
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 45.645
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202174 0 0 0 0 0 0 0 0 0 0 0 74
2021/2022585 37 129 12 34 8 31 30 52 43 48 58 103
2022/20231.153 107 121 75 118 79 230 0 61 277 4 50 31
2023/2024656 105 11 31 85 133 125 18 17 12 13 15 91
2024/20251.541 198 107 56 17 22 60 104 53 418 149 126 231
2025/20265.215 393 387 449 563 467 273 742 455 393 466 455 172
Totale 11.244